Investments
24Portfolio Exits
1
Want to inform investors similar to Trinity Innovation Fund about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Trinity Innovation Fund News
Dec 6, 2019
03:19 EST 6 Dec 2019 | ChinaBio Today Suzhou Ribo Life Science , a siRNA drug development company, raised $29 million in a series C1 financing led by Panlin Capital and Trinity Innovation Fund. Founded in 2007, Ribo formed a China JV in 2012 with Quark Pharma, a US siRNA company. The Quark JV produced Ribo's first China-approved therapy, a treatment for Ischemic Optic Neuropathy. The company claims expertise in small nucleic acid drug discovery, scale-up and production. Ribo, which has six Quark-partnered drug candidates plus four of its own molecules in development, says the siRNA treatments address multiple needs. More details.... Share this with colleagues:
Trinity Innovation Fund Investments
24 Investments
Trinity Innovation Fund has made 24 investments. Their latest investment was in Adcentrx Therapeutics as part of their Series A - II on April 4, 2023.
Trinity Innovation Fund Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/24/2023 | Series A - II | Adcentrx Therapeutics | $38M | Yes | ABio-X, Delta Capital, Eight Roads Ventures, F-Prime Capital, Trinity Innovation Fund, and Undisclosed Investors | 4 |
2/21/2023 | Series D - II | TransThera Biosciences | $37.8M | Yes | 1 | |
9/19/2022 | Seed VC | Ailomics Therapeutics | Yes | 2 | ||
8/8/2022 | Seed VC - II | |||||
7/29/2022 | Series E |
Date | 4/24/2023 | 2/21/2023 | 9/19/2022 | 8/8/2022 | 7/29/2022 |
|---|---|---|---|---|---|
Round | Series A - II | Series D - II | Seed VC | Seed VC - II | Series E |
Company | Adcentrx Therapeutics | TransThera Biosciences | Ailomics Therapeutics | ||
Amount | $38M | $37.8M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | ABio-X, Delta Capital, Eight Roads Ventures, F-Prime Capital, Trinity Innovation Fund, and Undisclosed Investors | ||||
Sources | 4 | 1 | 2 |
Trinity Innovation Fund Portfolio Exits
1 Portfolio Exit
Trinity Innovation Fund has 1 portfolio exit. Their latest portfolio exit was Dizal Pharma on December 10, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/10/2021 | IPO | Public | 1 |
Date | 12/10/2021 |
|---|---|
Exit | IPO |
Companies | |
Valuation | |
Acquirer | Public |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.